Abstract
Background
The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial.
Methods
After resection of pancreatic adenocarcinoma, patients were randomized to pre- and post-CRT 5-FU versus pre- and post-CRT gemcitabine. 5-FU was provided continuously at 250 mg/m2/day, and gemcitabine was provided at 1000 mg/m2 weekly. Both were provided over 3 weeks before and 12 weeks after CRT. CRT was provided at 50.4 Gy with continuously provided 5-FU. The primary end point was survival for all patients and for patients with tumor of the pancreatic head.
Results
Four hundred fifty-one patients were eligible. Univariate analysis showed no difference in OS. Pancreatic head tumor patients (n = 388) had a median survival and 5-year OS of 20.5 months and 22% with gemcitabine versus 17.1 months and 18% with 5-FU. On multivariate analysis, patients on the gemcitabine arm with pancreatic head tumors experienced a trend toward improved OS (P = 0.08). First site of relapse local recurrence in 28% of patients versus distant relapse in 73%.
Conclusions
The sequencing of 5-FU CRT with gemcitabine as done in this trial is not associated with a statistically significant improvement in OS. Despite local recurrence being approximately half of that reported in previous adjuvant trials, distant disease relapse still occurs in ≥70% of patients. These findings serve as the basis for the recently activated EORTC/U.S. Intergroup RTOG 0848 phase III adjuvant trial evaluating the impact of CRT after completion of a full course of gemcitabine.
Similar content being viewed by others
References
Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized trial. JAMA. 2007;297:267–77.
Neuhaus P, Riess H, Post S, et al. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008;26(suppl LBA4504).
Neoptolemos J, Buchler M, Stocken DD, et al. ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folonic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2009;27(suppl 18).
Regine WF, Winter K, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–26.
Nicecki SS, Sarr MG, Colby, TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995; 221:59–66.
Pirokowski RJ, Believernicht SW, Lawrence W Jr, et al. Pancreatic and periampullary carcinoma: experience with 200 patients over a 12-year period. Am J Surg. 1982;143:189–93.
Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer. 1987;60:2284–303.
Tepper J, Nardi G, Suit H. Carcinoma of the pancreas. Review of MGH experience from 1963–1973. Analysis of surgical failure and its implications for radiation therapy. Cancer. 1976;37:1519–24.
Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66:56–61.
Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.
Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 1999;230:776–82.
Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol. 2008;26:3511–6.
Herman JM, Schwartz MJ, Hsu CC, et al. Analysis of fluorouracil based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–10.
ID Fleming, JS Cooper, DE Henson, et al. (1997) Exocrine pancreas. In: American Joint Committee on Cancer manual for staging of cancer. 5th ed. Philadelphia, PA: Lippincott-Raven, p. 122–3.
Regine WF. Postoperative adjuvant therapy: past, present, and future trial development. In: Evans DB, Pisters PWT, Abbruzzese JL, eds. Pancreatic cancer. New York: Springer; 2006. p. 235–42.
Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365–75.
Montgomery RC, Hoffman JP, Riley LB, et al. Prediction of recurrence and survival by post-resection CA19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1958;4:551–6.
Kaplan EL, Meier P. Nonparameteric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.
Mantel N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep 50:163–70.
Cox DR. Regression models and life tables. J Royal Stat Soc Ser B. 1972; 34:187–229.
Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621–36.
Benson A. Adjuvant therapy for pancreatic cancer. JAMA. 2007;297:311–3.
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.
Moore MJ, Goldstin D, Hamm, et al. Erlotinib Plus Gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.
Acknowledgment
Supported by RTOG U10 CA21661 and CCOP U10 CA37422 grants from the NCI.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Regine, W.F., Winter, K.A., Abrams, R. et al. Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial. Ann Surg Oncol 18, 1319–1326 (2011). https://doi.org/10.1245/s10434-011-1630-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-1630-6